MS breakthrough? trial tests if older patients can ditch heavy drugs

This study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to milder treatments. The goal is to see if this de-escalation approach prevents disease activity and disability worsening just as well as staying on the stronger therapy. The trial will involve 250 participants and aims to reduce treatment burden while maintaining control of the disease.